WYDUR Board Meeting Minutes
Members Present: George Zaharas, Dean Winsch, Bill Harrison,
Richard Johnson, Becky Drnas, Linda Martin, Kendra Grande, Deb Devereaux,
Antoinette Brown, Aimee Lewis, Mike Carpenter, Steve Brown
Members Excused: Kay
Kohler, Scott Johnston
Guests: Lori Howarth, Berlex; Dennis Sagendorf, Purdue; Larry Bridger, Pfizer; Tm Vannaman, Takeda; Scott Berglan,
Takeda; Tim Hynek, Lilly; Chris Lepore,
Johnson&Johnson; Dyan
McGrath, AstraZeneca; Kara Smith, Boehringer
Ingelheim; Scott Willard, Boehringer
Ingelheim; Robert Calder, Merck; Jeff Jenkins, Merck
The meeting was called to
order at
The Department of Health
reported that from
The appeal review groups
are as follows:
NSAID, COX-2, PPI ACEI, Statins
Kendra George
Linda Dean
Becky Bill
Mike Lenny
Deb Richard
NSAIDs
The preferred NSAIDs are ibuprofen and naproxen (both prescription
strength). The COX-2 criteria will be
changed to “have to fail 2 NSAIDs”. There was discussion about generic NSAIDs not being preferred agents and the preferred agents
being limited to two.
The Board approved the
following prior authorization criteria for utilization on non-preferred NSAIDs:
Mefenamic acid (approval
for one year):
q Diagnosis of dysmenorrhea
Indomethocin (approval for one year):
q Diagnosis of gout
q Diagnosis of ankylosing spondylitis
q Diagnosis of pleurisy
q
Recent cardiac procedure
Diclofenac, etodolac or nabumetone (approval for one year):
q Patient is on concurrent low-dose aspirin therapy
q
Patient currently taking proton pump inhibitor,
at risk for GI bleed
Check one of the
following qualifications (approval for one year):
q Failure of preferred NSAID after 4 week trial
q Allergic reaction to preferred NSAID
q Intolerance or unacceptable adverse reaction to preferred NSAID
q Osteoarthritis
q Rheumatoid arthritis
q Ankylosing spondylitis
Ketorolac:
5 day limit, no prior authorization required
Statins
The preferred statin products are Lescol (fluvastatin) and Pravachol (pravastatin). The
Board approved the following prior authorization criteria for utilization of
non-preferred statins:
The Board discussed the
various roles of the DUR Board and the Preferred Drug List Advisory
Committee. The Board requested that the
PDLAC give consideration to issues of access and different dosage forms,
specifically long acting dosages. The
Board asked that the Department of Health continue to pursue the ability for
pharmacists to enter ICD9 codes electronically to expedite the prior
authorization process. The Board
expressed concern about cost shifting that may occur due to new lab tests and
office visits to change therapy. The question was also raised as to the
feasibility of new non-preferred statin prescriptions
being grandfathered for the remainder of the life of the prescription.
Open comments
Linda Pryor
(Pfizer)-general information about the Medicare Drug Benefit and the clawback provisions which may affect the PDL timeline,
patient access concerns, number of patients affected and the dollars saved
Dr. Calder (Merck)-results
of trials with Lescol and Pravachol
(30% reduction in cholesterol)
Dyan McGrath(AstraZeneca)-requested that the final report from the EPC
be reviewed when available, all patient data not available until final report
Alert changes
Suppress criteria #813 and
#537 (COX-2’s and warfarin)
The next meeting will be
There being no further
business the meeting was adjourned at
Respectfully Submitted,
Debra S. Devereaux
WYDUR Manager